To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)


Study Number
1333721
Phase
III
Age Group
Adult
Purpose

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

Full Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K; Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

ClinicalTrials.Gov ID
NCT04551066

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.